Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: OARS study

This article was originally published in The Gray Sheet

Executive Summary

OARS study: One-year follow-up of the 200-patient, multicenter Optimal Atherectomy Restenosis Study (OARS) shows a 18% repeat intervention rate in patients treated with "optimal atherectomy," researchers report Nov. 15 at the American Heart Association scientific sessions. Charles Simonton, MD, Carolinas Heart Institute, Charlotte, North Carolina, et al. say that the rate compares favorably with "the standard 28 to 30 percent rate for balloon angioplasty procedures. The investigators say that the optimal procedure, which involves multiple passes with Guidant's AtheroCath directional atherectomy device followed by balloon angioplasty, may "prove a more cost-effective choice than coronary stents." The 1,000-patient randomized Balloon Versus Optimal Atherectomy Trial (BOAT) is under way; preliminary data presented at AHA showed that optimal DCA is "effective in reducing acute residual diameter stenosis"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005071

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel